Laboratory of Animal Infectious Diseases and Molecular Immunology, College of Animal Science and Technology, Guangxi University, Nanning, China; Guangxi Zhuang Autonomous Region Engineering Research Center of Veterinary Biologics, Nanning, China; Guangxi Key Laboratory of Animal Reproduction, Breeding and Disease Control, Nanning, China.
Laboratory of Animal Infectious Diseases and Molecular Immunology, College of Animal Science and Technology, Guangxi University, Nanning, China; Guangxi Zhuang Autonomous Region Engineering Research Center of Veterinary Biologics, Nanning, China; Guangxi Key Laboratory of Animal Reproduction, Breeding and Disease Control, Nanning, China.
Virology. 2024 Dec;600:110260. doi: 10.1016/j.virol.2024.110260. Epub 2024 Oct 18.
Bovine enterovirus (BEV) infection manifests as a spectrum of clinical signs affecting the respiratory, gastrointestinal, and reproductive systems in cattle. Outbreaks of this disease results in large economic losses to the bovine industry worldwide. Currently there are no efficacious vaccines and medicines to prevent BEV infection. In the present study, reverse transcription-polymerase chain reaction was used to amplify the VP1 and VP2 genes of BEV, enabling the synthesis of a chimeric recombinant protein which contained partial sequences from both proteins. Subsequently, the emulsified purified proteins with Freund's adjuvant were used for triple-fold immunization of 4-week-old Institute of Cancer Research (ICR) mice. The mice were subsequently subjected to a challenge assay which elicited an immune response that was characterized by elevated titers of BEV-specific neutralizing antibodies. Notably, the results showed that the purification of pET32a-VP1 and pET32a-VP2 proteins markedly curtailed virus excretion and mitigated the histopathological damage usually associated with BEV infections. These were observed in the small intestines, kidneys and brain in infected animals. It also alleviated clinical symptoms such as hypothermia and weight loss. In summary, this study offers a theoretical and practical basis for BEV vaccine development.
牛肠道病毒（BEV）感染表现为一系列影响牛呼吸系统、胃肠道和生殖系统的临床症状。这种疾病的爆发会给全球的牛业造成巨大的经济损失。目前尚无有效的疫苗和药物来预防 BEV 感染。在本研究中，采用逆转录-聚合酶链反应扩增 BEV 的 VP1 和 VP2 基因，合成包含两种蛋白部分序列的嵌合重组蛋白。随后，用弗氏佐剂乳化纯化的蛋白对 4 周龄的癌症研究所（ICR）小鼠进行三重免疫。随后对小鼠进行了攻毒试验，引发了针对 BEV 的特异性中和抗体的免疫应答，其抗体滴度升高。值得注意的是，结果表明，pET32a-VP1 和 pET32a-VP2 蛋白的纯化显著减少了病毒的排出，并减轻了通常与 BEV 感染相关的组织病理学损伤。在感染动物的小肠、肾脏和大脑中观察到了这种情况。它还缓解了体温过低和体重减轻等临床症状。总之，本研究为 BEV 疫苗的开发提供了理论和实践基础。
